Yan Yin Technology and Dongyang Guang Medicine reach strategic cooperation
Recently,Qiming Venture Capital's portfolio company, Shanghai Yanin Technology Co., Ltd. ("Yanin Technology"), and Guangdong Dongyangguang Pharmaceutical Co., Ltd. ("Dongyangguang Pharmaceutical") officially announced a strategic partnership.The two parties will engage in in-depth cooperation in the development of AI agents, taking the AI translation agent project as an opportunity to develop core scenarios such as experimental design and IND submission, as well as AI laboratory automation robot scenarios. Together, they will explore the deep application of AI technology throughout the entire process of new drug development, accelerating Dongyangguang Pharmaceutical's global strategic layout.
As a leading enterprise in China's pharmaceuticals industry, Dongyang Light Pharmaceuticals is a comprehensive pharmaceutical company focusing on the R&D, production, and commercialization of innovative drugs.After more than two decades of development, Dongyangguang Pharmaceutical has established an independent, internationally standardized R&D platform and production facilities, boasting a strong and diversified product portfolio in the fields of infectious diseases, chronic conditions, and oncology. The company consistently adheres to independent R&D as its core driving force, actively applying AI technology to all stages of drug development to continuously enhance innovation capabilities and core competitiveness.
Yan Yin Technology is China's leading molecular biology research platform, committed to becoming a global leader in AI for R&D Cloud."Yan Yin Zhi Yan Cloud" is an enterprise-level biological research collaboration platform based on AI large models.The "AI Translation Agent" is an intelligent solution specifically designed for the biopharmaceutical field.It can provide one-stop services for a large number of professional documents involved in the overseas registration process of pharmaceutical products, including intelligent translation, model customization, post-translation editing, and cloud-based collaborative management, precisely addressing industry pain points.
Based on this collaboration, both parties will engage in long-term strategic cooperation and technical integration, aiming to bridge cutting-edge AI technology with practical business scenarios, enhance R&D efficiency, and create a new industry paradigm. This partnership not only serves as a strong testament to Yanyin Technology's AI technical capabilities but also lays a solid foundation for deeper collaboration in broader research scenarios in the future.
Vice General Manager of Guangdong East Sun Pharmaceutical Co., Ltd., Jin Chuanfei, stated: "Dongyangguang Pharmaceutical engages in the research, production, and sales of Class 1 new drugs, with a primary focus on three major areas: anti-infective, anti-tumor, and metabolic therapies."We hope to deepen our cooperation with Yan Yin Technology in AI agents and laboratory automation, leveraging AI to empower R&D business scenarios, and strive to create a new demonstration of intelligent biopharmaceutical R&D."
Dr. Zeping Chen, founder and CEO of Yan Yin Technology, said: "It is a great honor to gain the recognition and trust of Dongyangguang Pharmaceutical, a benchmark enterprise in the industry. Winning in such fierce competition is a high affirmation of Yanin Technology's technical strength and service philosophy."We will fully support Dongyangguang Pharmaceutical's global business, using the most advanced AI technology to enhance its research and operational efficiency. This is just the beginning; we look forward to working with Dongyangguang Pharmaceutical to explore the limitless possibilities of AI in the biopharmaceutical field and contribute more value to the industry."